Public Sector Pension Investment Board Grows Stock Holdings in Cencora, Inc. $COR

Public Sector Pension Investment Board raised its holdings in Cencora, Inc. (NYSE:COR) by 54.8% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 18,187 shares of the company’s stock after acquiring an additional 6,442 shares during the period. Public Sector Pension Investment Board’s holdings in Cencora were worth $5,684,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Cencora by 13.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 48,270 shares of the company’s stock valued at $15,086,000 after purchasing an additional 5,543 shares during the last quarter. Acadian Asset Management LLC boosted its stake in shares of Cencora by 947.5% during the 2nd quarter. Acadian Asset Management LLC now owns 257,082 shares of the company’s stock valued at $77,069,000 after buying an additional 232,539 shares during the last quarter. Mediolanum International Funds Ltd grew its position in shares of Cencora by 133.0% during the third quarter. Mediolanum International Funds Ltd now owns 56,293 shares of the company’s stock worth $17,342,000 after buying an additional 32,138 shares in the last quarter. Rhumbline Advisers increased its stake in shares of Cencora by 4.0% in the third quarter. Rhumbline Advisers now owns 430,150 shares of the company’s stock worth $134,435,000 after buying an additional 16,539 shares during the last quarter. Finally, Segment Wealth Management LLC acquired a new stake in Cencora in the third quarter valued at $4,830,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora News Roundup

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: The MWI–Covetrus merger values Cencora’s animal-health unit at ~$3.5B, providing proceeds and a clearer strategic focus on drug distribution — investors see this as de-risking and simplifying the company. Reuters: Cencora’s animal health unit to merge with Covetrus Philadelphia Business Journal: Cencora makes $3.5B deal
• Positive Sentiment: Coverage highlights that the divestiture lets Cencora refocus capital and management on higher-margin, core drug distribution operations — a narrative that can support multiple expansion. MSN: Cencora to refocus on drug distribution
• Neutral Sentiment: Analysts currently rate Cencora around a “moderate buy,” so the market reaction may be in line with expectations rather than a surprise re-rating. American Banking News: Consensus Moderate Buy
• Neutral Sentiment: Options activity suggests some traders are positioning for bigger moves, which can increase short-term volatility but doesn’t change fundamentals. Zacks: Options market activity
• Negative Sentiment: The deal reduces diversification and recurring revenue from animal health; proceeds may be one-time and the company still faces high leverage and integration/execution risk if transaction terms are complex. TMCNet: Covetrus and MWI Animal Health to Merge

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on COR shares. Robert W. Baird set a $415.00 target price on shares of Cencora in a research report on Tuesday, January 13th. Barclays boosted their price objective on Cencora from $400.00 to $425.00 and gave the company an “overweight” rating in a report on Friday, February 13th. Evercore reduced their target price on Cencora from $440.00 to $420.00 and set an “outperform” rating on the stock in a report on Thursday, February 5th. Wells Fargo & Company lifted their target price on Cencora from $405.00 to $429.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 10th. Finally, Weiss Ratings raised Cencora from a “hold (c+)” rating to a “buy (b)” rating in a research report on Thursday, February 5th. Eleven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, Cencora currently has a consensus rating of “Moderate Buy” and an average target price of $399.00.

Cencora Stock Up 0.1%

Shares of Cencora stock opened at $360.50 on Thursday. The stock has a market capitalization of $70.13 billion, a price-to-earnings ratio of 43.33, a PEG ratio of 1.66 and a beta of 0.68. Cencora, Inc. has a twelve month low of $240.10 and a twelve month high of $377.54. The company has a current ratio of 0.92, a quick ratio of 0.51 and a debt-to-equity ratio of 3.62. The business’s 50 day simple moving average is $348.82 and its 200-day simple moving average is $330.12.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $4.08 EPS for the quarter, topping analysts’ consensus estimates of $4.04 by $0.04. The firm had revenue of $85.93 billion during the quarter, compared to the consensus estimate of $86.12 billion. Cencora had a return on equity of 176.54% and a net margin of 0.50%.The firm’s revenue was up 5.5% on a year-over-year basis. During the same period in the prior year, the business earned $3.73 EPS. Equities research analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 2nd. Shareholders of record on Friday, February 13th will be paid a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend is Friday, February 13th. Cencora’s payout ratio is presently 28.85%.

Insiders Place Their Bets

In other Cencora news, CEO Robert P. Mauch sold 5,096 shares of the firm’s stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $354.73, for a total value of $1,807,704.08. Following the sale, the chief executive officer owned 66,726 shares in the company, valued at approximately $23,669,713.98. This trade represents a 7.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Elizabeth S. Campbell sold 3,351 shares of the business’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $342.10, for a total value of $1,146,377.10. Following the transaction, the executive vice president owned 23,891 shares of the company’s stock, valued at approximately $8,173,111.10. This represents a 12.30% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 15,220 shares of company stock worth $5,282,867. Insiders own 0.38% of the company’s stock.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.